Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05541328 · ClinicalTrials.gov registry record
Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 169
- Enrollment target
NCT05541328: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05541328 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 169 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05541328 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 169 participants
- Enrollment target
Study Summary
This is a non-interventional, retrospective cohort study using the Flatiron Health Research Database (FHRD) and data from the single-arm phase II JULIET clinical trial (NCT02445248).
Primary Outcome
To evaluate the efficacy of tisagenlecleucel therapy as compared to the current SOC as measured by overall survival (OS) among patients with r/r DLBCL and treated with at least two prior lines of systemic therapy.
Interventions
- OTHER Tisagenlecleucel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2020-02-03 |
| Est. Completion | 2021-02-05 |
What the finished NCT05541328 record still lists
NCT05541328 is an observational study that tracks outcomes without assigning an intervention. The registered 169 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Tisagenlecleucel is the first listed.
NCT05541328 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05541328 about?
NCT05541328 is a clinical study titled "Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel". This is a non-interventional, retrospective cohort study using the Flatiron Health Research Database (FHRD) and data from the single-arm phase II JULIET clinical trial (NCT02445248).
What is the current status of trial NCT05541328?
This trial is currently completed. The enrollment target is 169 participants. The study started on 2020-02-03. Estimated completion is 2021-02-05.
What interventions are being tested in trial NCT05541328?
The interventions under investigation include: Tisagenlecleucel (OTHER).
Who is sponsoring clinical trial NCT05541328?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06191484 · 169 participants · NA
Risk and Resilience to Suicide Following Late-Life Spousal Bereavement
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI